Controlled release of deferoxamine from niosomal nano-carrier for potential skin wound healing applications

The key factor in diabetic impaired wound healing is compromised fibroblast healing ability and also damaged and therefore poor angiogenesis. Deferoxamine (DFO) as an iron-chelating agent is conventionally used for treatment of iron overload. However, it could be applied as an angiogenic therapeutic agent, improving wound healing by activation of the hypoxia inducible factor-1a (HIF-1a) pathway. Despite its effectiveness in wound site, its short half-life made it not effective enough as a therapeutic agent. In current research a niosomal DFO nano-carrier were designed and fabricated in order to make a sustained and controlled release nanostructure and then were evaluated. Due to low bio-stability, DFO was encapsulated into nano-niosome using thin film hydration method and then its morphology, size distribution, chemical structure and drug release pattern were evaluated. An average size of DFO loaded niosomes and the entrapment efficacy were 200-300 nm and 81.4%, respectively. In vitro release assessment during 14 days suggested that approximately 20% of total encapsulated drug were released in the first week. Finally, it could be concluded that the nano-niosomal DFO could be suggested as a wound dressing products for sustained and localized release

Keywords:

Deferoxamine (DFO) , Noisome , Controlled release , Nano-carrier , Wound healing